Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Harvard Business School
McKesson
Colorcon
Baxter

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Patent: 9,789,165

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,789,165
Title:Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
Inventor(s): Kadereit; Dieter (Frankfurt am Main, DE), Lorenz; Katrin (Frankfurt am Main, DE), Evers; Andreas (Frankfurt am Main, DE), Haack; Torsten (Frankfurt am Main, DE), Wagner; Michael (Frankfurt am Main, DE), Henkel; Bernd (Frankfurt am Main, DE), Lorenz; Martin (Frankfurt am Main, DE), Stengelin; Siegfried (Frankfurt am Main, DE)
Assignee: SANOFI (Paris, FR)
Application Number:14/569,055
Patent Claims:see list of patent claims

Details for Patent 9,789,165

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 1982-10-28 ⤷  Free Forever Trial 2033-12-13
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 2015-12-29 ⤷  Free Forever Trial 2033-12-13
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 1998-08-06 ⤷  Free Forever Trial 2033-12-13
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 1994-03-31 ⤷  Free Forever Trial 2033-12-13
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 2018-05-25 ⤷  Free Forever Trial 2033-12-13
Novo Nordisk Inc. NOVOLIN R insulin human Injection 019938 1991-06-25 ⤷  Free Forever Trial 2033-12-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
McKinsey
Johnson and Johnson
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.